Finn Samuelsen resigns, initiating search for new permanent CFO
(Thomson Reuters ONE) - Finn Samuelsen has decided to resign from his position as CFO inBiotec Pharmacon, following a long period on sick leave. The companynow initiates a process to hire a new CFO on a permanent basis.Jørn Lunde who has been hired in as acting CFO, has informed thecompany that he has decided not to take on the position on apermanent basis. Lunde will continue until a new CFO is in place.For further information, please contact CEO Lars Viksmoen on tel: +4740620870.About Biotec Pharmacon:The biopharmaceutical company Biotec Pharmacon developspharmaceutical products for prevention and treatment of immunerelated diseases. The company has developed the bioactive substanceSBG (soluble beta glucan), which is in clinical phase III for twoindications; treatment of diabetic ulcers and prevention andtreatment of oral mucositis. The company's clinical developmentprogram also includes immune therapy of cancer, where combinationtreatments with SBG and monoclonal antibodies are being studied inclinical phase I/II. In addition, the company is involved in severalpreclinical studies with SBG. Biotec Pharmacon also produces andmarkets non-pharmaceutical health and diagnostic products, throughthe 100% owned companies Immunocorp Consumer Health AS and the marineenzyme company Biotec Marine Biochemicals AS.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 03.11.2009 - 08:29 Uhr
Sprache: Deutsch
News-ID 7816
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Finn Samuelsen resigns, initiating search for new permanent CFO"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
